for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

57.22EUR

Change

0.50(+0.88%)

Volume

7,344,395

Today's Range

56.64

 - 

57.70

52 Week Range

44.85

 - 

78.34

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
56.72
Open
56.83
Volume
7,344,395
3M AVG Volume
70.14
Today's High
57.70
Today's Low
56.64
52 Week High
78.34
52 Week Low
44.85
Shares Out (MIL)
982.42
Market Cap (MIL)
55,723.09
Forward P/E
8.56
Dividend (Yield %)
4.94

Next Event

Q3 2020 Bayer AG Earnings Release

Latest Developments

More

Bayer Collaborates With Recursion To Strengthen Digital Drug Discovery

Bayer Completes Acquisition Of Kandy Therapeutics

Bayer Says Phase 4 Study Met Its Main Goal In PAH Patients Who Transitioned To Adempas

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bayer AG

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

Industry

Major Drugs

Contact Info

Kaiser-Wilhelm-Allee 1

51373

Germany

+49.214.301

https://www.bayer.de/

Executive Leadership

Norbert Winkeljohann

Chairman of the Supervisory Board

Werner Baumann

Chairman of the Management Board, Chief Executive Officer

Oliver Zuehlke

Independent Vice Chairman of the Supervisory Board, Employee Representative

Wolfgang U. Nickl

Chief Financial Officer, Member of the Management Board

Liam Condon

Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit

Key Stats

2.07 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.0K

2018

39.6K

2019

43.5K

2020(E)

43.4K
EPS (EUR)

2017

6.633

2018

5.940

2019

6.400

2020(E)

6.624
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.28
Price To Book (MRQ)
1.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
115.73
LT Debt To Equity (MRQ)
95.08
Return on Investment (TTM)
-7.66
Return on Equity (TTM)
-5.77

Latest News

Latest News

Exclusive: In the weeds - How Bayer, U.S. government teamed up against Thailand's glyphosate ban

Chemicals giant Bayer and the U.S. government cooperated closely last year to lobby Thailand to reverse its ban on glyphosate, used in the company's controversial weedkiller Roundup, documents obtained by an environmental group and reviewed by Reuters show.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer in deal with Systems Oncology over novel breast cancer drug

Bayer said on Tuesday it had secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.

UPDATE 3-Bayer CEO's term extended, makes progress on Roundup settlement

* Shares gain on prospect of resolution (Adds shares, investor comment)

Bayer appeals $20.5 million Roundup ruling to California Supreme Court

Bayer AG has asked California's Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company's Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Bayer appeals $20.5 mln Roundup ruling to California Supreme Court

Bayer AG has asked California's Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company's Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Bayer acknowledges 'bumps' in $11 billion Roundup deal after judge raises doubts

Shares in German drugs company Bayer AG <BAYGn.DE> fell 3% on Friday after it said there were "bumps" in sealing its $11 billion (8.29 billion pounds) settlement of U.S. lawsuits over its Roundup weed killer after a U.S. judge cast doubt on the progress of the agreement.

Bayer-Roundup $11 bln deal at risk of collapse, judge says - Bloomberg News

German drugs company Bayer AG's $11 billion settlement of thousands of U.S. lawsuits over its Roundup weed killer is less defined than the company disclosed, a judge overseeing the suits said, Bloomberg News reported on Thursday.

U.S. Black farmers seek ban or product warnings for Roundup weedkiller

A group of Black U.S. farmers filed a federal lawsuit on Wednesday, seeking to force Bayer AG to either stop selling its widely used weedkiller Roundup or roll out new product warnings.

Bayer to pay $1.6 billion to resolve U.S. claims for Essure birth-control device

German drugs and pesticides group Bayer <BAYGn.DE> said on Thursday it will pay around $1.6 billion to settle the majority of U.S. claims involving its Essure birth-control device.

Bayer to pay $1.6 bln to resolve U.S. suits for Essure birth-control device

Bayer said on Thursday it will pay around $1.6 billion to settle the majority of U.S. claims involving its Essure birth-control device.

Bayer takes on Astellas in purchase of experimental menopause relief

Bayer <BAYGn.DE> moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas <4503.T>.

Bayer buys British developer of treatment for menopausal symptoms

Bayer agreed to acquire British biotech firm KaNDy Therapeutics Ltd. for an initial $425 million to strengthen its women's healthcare business with a prospective non-hormonal treatment of menopausal symptoms.

Regeneron profit beats, expects early results from COVID-19 trials in September

Regeneron Pharmaceuticals Inc <REGN.O> beat second-quarter profit estimates on Wednesday, helped by higher sales of its eczema drug Dupixent and said it expects initial data from ongoing trials of its COVID-19 antibody cocktail next month.

Bayer says struggling to find patients for precision cancer drug Vitrakvi

Bayer said it is finding it hard to identify cases of the rare tumour types that qualify for treatment with Vitrakvi, a precision cancer drug which it hopes will improve prospects of its drugs division.

Bayer chalks up 9.5 billion euro second-quarter net loss after litigation settlement

German drugs and pesticides group Bayer reported a 9.5 billion euro ($11.2 billion) net loss for the second quarter, following a $10.9 billion settlement of U.S. lawsuits claiming that its weedkiller Roundup caused cancer.

Weak Diageo, Bayer earnings hit Europe stocks; BP jumps

European shares edged lower on Tuesday as disappointing earnings reports from Diageo and Bayer took the shine off a jump in growth-linked cyclical stocks, while investors awaited signs of progress on more U.S. fiscal stimulus.

Bayer chalks up 9.5 bln eur Q2 net loss after litigation settlement

German drugs and pesticides group Bayer reported a 9.5 billion euro ($11.2 billion) net loss for the second quarter, following a $10.9 billion settlement of U.S. lawsuits claiming that its weedkiller Roundup caused cancer.

Elanco's Brazil unit taps new executive as $6.89 billion Bayer deal concluded

Sérgio Schuler was appointed director general of Elanco Animal Health Inc's <ELAN.N> Brazil unit after the U.S.-based veterinary products firm completed its acquisition of Bayer's <BAYGn.DE> animal health division on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up